Continuation versus Interruption of Oral Anticoagulation during TAVI
In patients undergoing TAVI with a concomitant indication for oral anticoagulation, periprocedural continuation was not noninferior to interruption of oral anticoagulation during TAVI with respect to the incidence of a composite of death from cardiovascular causes, stroke, myocardial infarction, major vascular complications, or major bleeding at 30 days. (Funded by the Netherlands Organization for Health Research and Development and the St. Antonius Research Fund; POPular PAUSE TAVI ClinicalTrials.gov number, NCT04437303.).
Authors
- Nicolas M. Van Mieghem (ORCID: https://orcid.org/0000-0002-2732-1205)
- Peter Frambach
- Joyce Peper (ORCID: https://orcid.org/0000-0002-4008-1656)
- Alexander Ijsselmuiden
- Leo Veenstra
- Pierfrancesco Agostoni (ORCID: https://orcid.org/0000-0002-1505-9369)
- Jurriën M. ten Berg (ORCID: https://orcid.org/0000-0001-5192-886X)
- Joanna J. Wykrzykowska (ORCID: https://orcid.org/0000-0001-7577-4084)
- Jan A.S. Van der Heyden
- Renicus S. Hermanides (ORCID: https://orcid.org/0000-0003-3931-2565)
- Kees H. van Bergeijk (ORCID: https://orcid.org/0000-0001-6271-0567)
- Jorn Brouwer (ORCID: https://orcid.org/0000-0002-7815-1031)
- Ole De Backer (ORCID: https://orcid.org/0000-0002-9674-0278)
- Hicham El Jattari (ORCID: https://orcid.org/0000-0002-0608-8002)
- José M. Montero Cabezas (ORCID: https://orcid.org/0000-0002-3851-5195)
- Liesbeth Rosseel (ORCID: https://orcid.org/0000-0002-3940-3072)
- Christophe Dubois (ORCID: https://orcid.org/0000-0003-2421-6087)
- Yusuke Kobari (ORCID: https://orcid.org/0000-0002-6144-9747)
- Remigio Leonora
- Niels van Royen (ORCID: https://orcid.org/0000-0001-6136-8640)
- Hugo M. Aarts (ORCID: https://orcid.org/0000-0003-0852-8275)
- Maxim J P Rooijakkers (ORCID: https://orcid.org/0000-0002-6815-7667)
- Bert Ferdinande (ORCID: https://orcid.org/0000-0003-4492-2675)
- Martin J. Swaans (ORCID: https://orcid.org/0000-0003-1608-2760)
- Carl E. Schotborgh (ORCID: https://orcid.org/0000-0001-7630-0868)
- Marc Vanderheyden (ORCID: https://orcid.org/0000-0003-3050-5221)
- Pieter A. Vriesendorp (ORCID: https://orcid.org/0000-0002-2961-8600)
- Emanuele Barbato (ORCID: https://orcid.org/0000-0002-0050-5178)
- Willem L. Bor (ORCID: https://orcid.org/0000-0002-3253-5961)
- Frank van der Kley (ORCID: https://orcid.org/0000-0003-4521-8698)
- Enrico Fabris (ORCID: https://orcid.org/0000-0001-9458-0736)
- Michael Lauterbach (ORCID: https://orcid.org/0000-0002-0763-7325)
- Jonathan Halim (ORCID: https://orcid.org/0000-0002-4451-6848)
- Leo Timmers (ORCID: https://orcid.org/0000-0001-9788-9392)
- Vincent J. Nijenhuis (ORCID: https://orcid.org/0000-0003-0030-7427)
- Arnoud W.J. van ‘t Hof (ORCID: https://orcid.org/0000-0002-2344-7564)
- Ronak Delewi (ORCID: https://orcid.org/0000-0001-6070-9423)
- Daniël C. Overduin (ORCID: https://orcid.org/0009-0004-1368-5499)
- Jan G.P. Tijssen (ORCID: https://orcid.org/0000-0003-1707-2628)
- Michiel Voskuil (ORCID: https://orcid.org/0000-0003-1789-8462)
- Tom Adriaenssens (ORCID: https://orcid.org/0000-0001-9892-5420)
- Darren Mylotte
- Dirk Jan van Ginkel
- Benno J. Rensing (ORCID: https://orcid.org/0000-0002-8637-5166)
- Karl Dujardin
- Ben J L Van den Branden
Institutions
- Radboud University Nijmegen (NL)
- Radboud University Medical Center (NL)
- University Medical Center Utrecht (NL)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2024-08-31
- DOI
- https://doi.org/10.1056/nejmoa2407794
- Citations
- 28
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 11.26
Funders
- ZonMw